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Abstract
Background: Optimal glycemic control prevents the onset of diabetes complications. Identifying
diabetic patients at risk of poor glycemic control could help promoting dedicated interventions.
The purpose of this study was to identify predictors of poor short-term and long-term glycemic
control in older diabetic in-patients.
Methods: A total of 1354 older diabetic in-patients consecutively enrolled in a multicenter study
formed the training population (retrospective arm); 264 patients consecutively admitted to a ward
of general medicine formed the testing population (prospective arm). Glycated hemoglobin
(HbA1c) was measured on admission and one year after the discharge in the testing population.
Independent correlates of a discharge glycemia ≥  140 mg/dl in the training population were
assessed by logistic regression analysis and a clinical prediction rule was developed. The ability of
the prediction rule and that of admission HbA1c to predict discharge glycemia ≥  140 mg/dl and
HbA1c > 7% one year after discharge was assessed in the testing population.
Results: Selected admission variables (diastolic arterial pressure < 80 mmHg, glycemia = 143–218
mg/dl, glycemia > 218 mg/dl, history of insulinic or combined hypoglycemic therapy, Charlson's
index > 2) were combined to obtain a score predicting a discharge fasting glycemia ≥  140 mg/dl in
the training population. A modified score was obtained by adding 1 if admission HbA1c exceeded
7.8%. The modified score was the best predictor of both discharge glycemia ≥  140 mg/dl (sensitivity
= 79%, specificity = 63%) and 1 year HbA1c > 7% (sensitivity = 72%, specificity = 71%) in the testing
population.
Conclusion: A simple clinical prediction rule might help identify older diabetic in-patients at risk
of both short and long term poor glycemic control.
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Background
Optimal glycemic control has been proved to prevent the
onset and/or to slow the progression of several complica-
tions of diabetes and, thus, to improve quality of life [1–
4]. Guidelines have been proposed to optimize the man-
agement of outpatients with diabetes and to assess the
quality of the achieved glycemic control [5–16]. Attention
has not been paid to the quality of glycemic control in
people admitted to acute care hospital. Indeed, glycemic
levels during the hospital stay, i. e. during a few days, are
expected to lack any effect on the risk of complications
which is related to the quality of glycemic control through
several years. However, diabetic in-patients might repre-
sent a convenient sample for verifying whether any rela-
tionship exists between admission clinical/laboratory
characteristics and the quality of glycemic control
achieved at discharge and one year later. Targeting pa-
tients at risk of poor long term glycemic control could
help promoting strategies to improve the quality of diabe-
tes care.
Older diabetics represent the ideal population to be tar-
geted because logistic problems frequently limit their ac-
cess to ambulatory health care facilities. Furthermore,
standards of care have been reported to be quite poor for
a considerable proportion of older Medicare diabetic pa-
tients [17].
The present study has two objectives: 1) to develop a clin-
ical prediction rule targeting older patients at risk of being
discharged in poor glycemic control; 2) to verify whether
the same prognostic model can predict long term poor
glycemic control, as expressed by HbA1c > 7% one year
later.
Methods
Study design
The first part of this study aimed at developing a predic-
tive score targeting subjects at risk of poor glycemic con-
trol at discharge in a population of diabetic patients
enrolled in the GIFA (Gruppo Italiano di Farmacovigilan-
za nell'Anziano) study (retrospective arm of the study).
The predictive score was, then, prospectively validated in
a population of 264 diabetic in-patients consecutively ad-
mitted to a ward of general medicine. Accordingly, we will
define "training" and "testing" population the ones in
which the score was developed and validated, respectively
[18]. The ability of both predictive score and admission
HbA1c values to predict abnormal HbA1c one year after
discharge was assessed in the testing population. The
study design was approved by Ethical Committees of par-
ticipating institutions. Patients gave their informed con-
sent to participate in the study. The study design is
summarized in figure 1 (see additional file: figure1.ppt).
Training population: data source
We used data collected by the GIFA in six non consecutive
periods (May – June and September – October in the years
1993, 1995 and 1997). The design of the GIFA study has
been described elsewhere [19,20]. The study aimed at as-
sessing drug use at home and in the hospital by a stand-
ardized protocol. All patients admitted to participating
centers (32 wards of Geriatrics and 37 wards of Internal
Medicine) during the study period were recruited without
exclusion criteria. A study physician completed a ques-
tionnaire on admission recording demographic and per-
sonal information (such as smoking habit, household
composition), functional and cognitive status. Results of
laboratory tests performed at admission and at the time of
discharge were also collected. Serum glucose was assessed
by the hexokinase method. The study physician updated
the questionnaire daily with detailed information on the
therapy prescribed and finally recorded discharge diag-
noses and prescriptions.
Training population: selection criteria
The number of patients enrolled in the GIFA study in the
period we considered was 14,037. We excluded persons
younger than 65 years (n = 3,311) and those who died
during the hospital stay (n = 751). Of the 9,982 remaining
patients, 1,833 (18.4%) had a diagnosis of diabetes mel-
litus, identified by the codes 250.0 – 250.6; 250.7; 250.9;
337.1 – 357.2; 354.5; 355.9; 358.1; 362.0; 366.4; 443.8,
581.8, 582.8, 583.8 of the International Classification of
Disease [21]. We then excluded those with missing data
on glycemia or any other of the variables to be tested as
potential correlates of the quality of achieved glycemic
control (n = 479). These variables assess health status,
type of hypoglycemic therapy prior to admission, comor-
bidity and severity of the metabolic derangement, as ex-
pressed by selected laboratory and clinical parameters.
The 1,354 remaining patients formed the training popula-
tion.
Training population: clinical measures
Height and weight were measured while the patient was
fasting and wore light clothing. Weight of dehydrated or
edematous patients was measured after the achievement
of the euvolemic status. Then, Body Mass Index (BMI =
weight/height2) was computed.
We measured the performance on the Activities of Daily
Living (ADLs: dressing, bathing, transferring, toileting,
walking, eating) [22], and divided patients in the follow-
ing three categories: independent in all ADLs, dependent
on external help in 1 to 5 ADLs, dependent on external
help in all ADLs.
Cognitive status was assessed by the Abbreviated Mental
Test (AMT), which is a 10-item screening test for dementiaBMC Geriatrics 2002, 2 http://www.biomedcentral.com/1471-2318/2/4
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validated in Italy [23,24]. We considered abnormal a
score lower than 7. This cut-off level for AMT score has
been reported to yield 100% sensitivity and 71% specifi-
city with respect to the DSM III diagnosis criteria of de-
mentia [24].
Comorbidity was measured according to Charlson et al.
[25].
The hospital staff measured arterial blood pressure at the
time of the patient's admission. The average of two con-
secutive measurements was considered. Heart rate was
measured on an electrocardiographic strip.
On admission, the study physician requested the patients
and/or, if necessary, their relatives or caregivers to display
all containers for drugs taken during the last two weeks
prior to admission or to recall the names of drugs. Also,
the study physician recorded daily all the drugs prescribed
during the hospital stay (including dosage), as well as
those prescribed at discharge. Drugs were codified accord-
ing to Anatomical, Therapeutic and Chemical codes, ver-
sion 9th [26]. In the present study, we considered only
oral hypoglycemic agents and insulin for analysis.
Testing population
It included 264 diabetic patients selected out of the 399
admitted to a ward of general medicine of an acute care
hospital (University Hospital of Messina) in 1999–2000
to be matched to the training population for age, gender
and education as well as for performance on AMT and
ADL (prospective arm of the study). Discharged patients
were seen by internists in the outpatient department every
3 to 6 months depending upon the individual needs.
Clinical characteristics and values of selected laboratory
indexes were systematically collected as in the training
population. HbA1c levels were measured by HPLC (Dia-
Figure 1
Design of the study.
Training Population
GIFA dataset 1993-1997
Diabetic patients (N=1354)
Identification of risk factors associated
to the outcome fasting glucose at
discharge ≥ 140 mg/dl
Calculation of a score identifying
diabetic patients at risk of poor
glycemic control
Testing Population
Diabetic patients (N=264)
Evaluation of the association between
the score and the outcome fasting
glucose at discharge ≥ 140 mg/dl
Evaluation of the association between
t h es c o r eo rH b A 1 c>7 . 8 %a tt h e
admission and the outcome HbA1c > 7
1 year after the discharge
Retrospective arm Retrospective arm of the of the study study Prospective arm Prospective arm of the of the study studyBMC Geriatrics 2002, 2 http://www.biomedcentral.com/1471-2318/2/4
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man DM BioRad, Segrate – Milano, Italy) both on admis-
sion and one year after the discharge. The latter
measurement was made on 199 patients. Nineteen out of
the remaining 65 patients were dead at the time of follow
up, whereas 46 refused to participate or could not be
tracked.
Data analysis
In order to define the profile of patients at risk of poor gly-
cemic control, we considered socio-demographic data
(age, sex, years of formal education), select laboratory
findings (glycemia, cholesterol, triglycerides, sodium, po-
tassium, creatinine, white cell count), BMI, Charlson's in-
dex, AMT and ADL scores. We categorized laboratory
parameters using the tertiles of their distribution to make
the comparisons more meaningful from a clinical point of
view. We classified anti-diabetic therapy as follows: diet
alone if no drugs were prescribed, oral hypoglycemic ther-
apy alone, insulin alone, combined oral hypoglycemic
therapy and insulin.
The glycemic control achieved at discharge was consid-
ered as inadequate if fasting glycemia exceeded 140 mg/dl
[27]. This threshold was used because the study period an-
tedated the revision of normal glycemic standards pro-
posed in 1999 [28]. Admission variables univariately
associated with the outcome glycemia ≥  140 mg/dl at dis-
charge were entered into a logistic regression analysis
aimed at identifying independent correlates of the out-
come [29]. Selected variables were excluded from the lo-
gistic regression to limit multicollinearity with admission
glycemia. The analysis was repeated for patients admitted
to the hospital after the introduction of the Diagnosis Re-
lated Payment (DRG) system as well as for those who
were hospitalized primarily because of diabetes mellitus.
This precautionary measure aimed at excluding that the
DRG-related shortening of the stay and/or differences in
the clinical importance of diabetes could affect the model
predicting poor glycemic control at discharge.
We developed a score to target patients at risk of poor gly-
cemic control. Variables recognized to be independently
Table 1: Comparison among training population and patients excluded from the analysis because of missing data
Training population
 (N = 1354)
Patients excluded
 (N = 479)
tP
Age (yrs) 77.0 ± 6.7 77.9 ± 7.2 -2.524 0.012
Gender (males) 577 (42.6) 209 (43.6) 0.699
BMI (kg/m2) 26.3 ± 4.8 25.6 ± 4.6 2.495 0.013
Systolic blood pressure (mmHg) 149 ± 26 149 ± 25 -0.038 0.969
Diastolic blood pressure (mmHg) 82 ± 14 82 ± 13 0.591 0.555
Education (yrs) 5.4 ± 3.3 5.0 ± 2.9 2.377 0.018
Type of ward 0.023
Geriatrics 961 (71.0) 343 (71.6)
Medicine 366 (27.0) 135 (28.2)
Others 27 (2.0) 1 (0.2)
Charlson 2.5 ± 1.8 2.5 ± 1.6 0.878 0.380
AMT 6.9 ± 3.0 6.9 ± 3.1 0.308 0.758
ADL 0.821
Independent 661 (48.8) 234 (48.9)
Assistance 292 (21.6) 98 (20.5)
Dependent 390 (28.8) 144 (30.1)
Hypoglycemic therapy prior to admission 0.002
Diet alone 659 (48.7) 263 (54.9)
Oral agents alone 444 (32.8) 160 (33.4)
Insulin alone 213 (15.7) 42 (8.8)
Oral agents and insulin 38 (2.8) 14 (2.9)
Plasma glucose (mg/dl) 198 ± 102 159 ± 78 7.459 0.001
Cholesterol (mg/dl) 189 ± 53 184 ± 51 1.658 0.098
Triglycerides (mg/dl) 162 ± 108 149 ± 98 2.020 0.044
White blood cells (cells/mm3) 8576 ± 4337 8564 ± 6100 0.044 0.965
Serum sodium (mEq/l) 139 ± 4.5 139 ± 4.3 -0.354 0.723
Serum potassium (mEq/l) 4.3 ± 0.6 4.3 ± 0.6 2.275 0.023
Data are means ± SD or number of cases with percent in parentheses.BMC Geriatrics 2002, 2 http://www.biomedcentral.com/1471-2318/2/4
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Table 2: Demographic, historical, clinical and laboratory correlates of fasting plasma glucose ≥  140 mg/dl at discharge in the training 
population
Fasting plasma glucose at discharge
< 140 ≥  140 OR* 95% CI
Age (yrs) 76.8 ± 6.8 77.2 ± 6.7 1.01 0.99–1.02
Gender (males) 332 (44.9) 245 (39.8) 0.82 0.66–1.02
BMI (kg/m2) 26.1 ± 4.8 26.7 ± 4.8 1.02 1.0–1.05
Systolic blood pressure (mmHg)
<140 130 (17.6) 116 (18.9) 1.0
140–160 370 (50.1) 299 (48.6) 0.89 0.66–1.19
>160 239 (32.3) 200 (32.5) 0.92 0.67–1.26
Diastolic blood pressure (mmHg)
<80 101 (13.7) 126 (20.5) 1.0
80–90 452 (61.2) 320 (52.0) 0.56 0.41–0.75
>90 186 (25.2) 169 (27.5) 0.71 0.51–0.99
Education (yrs)
< 5 240 (32.5) 227 (36.9) 1.0
5–8 349 (47.2) 261 (42.4) 0.82 0.64–1.05
> 8 91 (12.3) 57 (9.3) 0.70 0.47–1.04
Type of ward
Geriatrics 532 (72.0) 429 (69.8) 1.0
Medicine 195 (26.4) 171 (27.8) 1.09 0.86–1.39
Others 12 (1.6) 15 (2.4) 1.63 0.75–3.53
Charlson
0–1 265 (35.9) 206 (33.5) 1.0
2 193 (26.1) 136 (22.1) 0.92 0.69–1.23
3+ 281 (38.0) 273 (44.4) 1.28 1.01–1.64
AMT
≥  7 483 (65.4) 386 (62.8) 1.0
< 7 244 (33.0) 216 (35.1) 1.06 0.83–1.34
ADL
Independent 365 (49.4) 296 (48.1) 1.0
Assistance 175 (23.7) 117 (19.0) 0.80 0.60–1.06
Dependent 192 (26.0) 198 (32.2) 1.23 0.95–1.60
Hypoglycemic therapy prior to admis-
sion
Diet alone 386 (52.2) 273 (44.4) 1.0
Oral agents alone 253 (34.2) 191 (31.1) 1.05 0.83–1.35
Insulin alone 86 (11.6) 127 (20.7) 2.07 1.51–2.84
Oral agents and insulin 14 (1.9) 24 (3.9) 2.40 1.22–4.74
Plasma glucose (mg/dl)
< 143 344 (46.5) 110 (17.9) 1.0
143–218 233 (31.5) 218 (35.4) 2.90 2.18–3.85
> 218 162 (21.9) 287 (46.7) 5.50 4.12–7.34
Cholesterol (mg/dl)
< 164 237 (32.1) 183 (29.8) 1.0
164–208 245 (33.2) 185 (30.1) 0.96 0.73–1.26
> 208 212 (28.7) 209 (34.0) 1.24 0.93–1.63
Triglycerides (mg/dl)
< 110 232 (31.4) 143 (23.3) 1.0
110–168 217 (29.4) 175 (28.5) 1.31 0.98–1.75
> 168 185 (25.0) 193 (31.4) 1.67 1.24–2.23
White blood cells (cells/mm3)
< 6800 248 (33.6) 196 (31.9) 1.0
6800–8970 262 (35.5) 186 (30.2) 0.90 0.69–1.17
> 8970 224 (30.3) 225 (36.6) 1.28 0.98–1.67BMC Geriatrics 2002, 2 http://www.biomedcentral.com/1471-2318/2/4
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correlated with the outcome were assigned a score whose
magnitude ranged between 0 and 5 and was directly pro-
portional to the corresponding odds ratio. The final score
for the individual patient was obtained by summing par-
tial scores, i. e. those corresponding to predictors collected
in that patient. The ability of the score to predict the out-
come glycemia ≥  140 mg/dl control at discharge and the
best cut off value of the score were assessed by measuring
the area under the receiving operating characteristic
(ROC) curve in the testing population [30].
Statistical analysis was performed using SPSS software
package version 10.0 (SPSS Inc, Chicago, IL, USA).
The predictive score was validated in the testing popula-
tion. In this population, we calculated also the sensitivity
and specificity of HbA1c in detecting the probability of
poor glycemic control at discharge, using a cut off value of
7.8 %, which was empirically identified as the best cut off
level. We obtained a modified score by adding 1 to the
original score in patients with admission HbA1c > 7.8%.
Finally, we compared the diagnostic accuracy of the three
predictors (the predictive score, HbA1c >7.8% on admis-
sion, and the modified score) versus the outcome HbA1c
> 7% one year after the discharge.
Results
The main characteristics of the training population and of
patients excluded from the study because of incomplete
data recording are reported in Table 1. Excluded patients
were slightly older and had lower formal education and
BMI, but comparable level of comorbidity, physical and
cognitive performance. They were in better metabolic con-
trol, as reflected by lower admission serum glycemia and
triglycerides and lesser use of insulin prior to admission
(Table 1).
Patients enrolled in the training population were grouped
according to whether their glycemia at discharge was or
not inferior to 140 mg/dl (Table 2). Groups had compara-
ble age, prevalence of males, educational level, nutritional
status, cognitive and physical capabilities. Diabetes melli-
tus was the cause of hospitalization in 16.1% of patients
discharged with glycemia < 140 mg/dl and 22.6% of pa-
tients discharged with glycemia >139 mg/dl. The alloca-
tion to a ward of Geriatrics or General Medicine was
unrelated to the outcome glycemic control, whereas the
use of insulin alone or with oral hypoglycemic agents pri-
or to admission, diastolic hypotension on admission and
a Charlson's index greater than 2 were more common
among patients having fasting glycemia ≥  140 mg/dl at
discharge. The higher the glycemia on admission the
greater the risk of not achieving a satisfactory glycemic
control at discharge. Also hypertrygliceridemia and hy-
ponatremia on admission were more prevalent among pa-
tients discharged with glycemia ≥  140 mg/dl.
Logistic regression analysis identified five admission vari-
ables independently correlated with poor glycemic con-
trol at discharge: diastolic arterial pressure lower than 80
mmHg, glycemia = 143–218 mg/dl, glycemia > 218 mg/
dl, use of insulin with or without oral hypoglycemic
agents in the two weeks prior to admission, Charlson's in-
dex > 2 (Table 3). We did not include hypertrygliceri-
demia in the model because of the collinearity with
admission hyperglycemia, which likely reflects the paral-
lelism between serum levels of glucose and tryglicerides in
decompensated diabetes. Logistic regression analyses lim-
ited to the DRG era (1995–1997) and to patients for
whom diabetes was the cause of admission confirmed re-
sults achieved in the whole population.
In an attempt to interpret the relationship between lower
diastolic pressure and poor metabolic control, we charac-
terized hypotensive patients and found that a greater
Charlson's index (2.8 ± 2.2 vs. 2.5 ± 1.7, p < 0.005) and
lower cholesterol level (169 ± 50 vs. 193 ± 53 mg/dl, p <
.001) were the hallmark of this subset.
Serum sodium (mEq/l)
< 138 185 (25.0) 210 (34.1) 1.0
138–141 300 (40.6) 230 (37.4) 0.68 0.52–0.88
>141 242 (32.7) 169 (27.5) 0.61 0.46–0.80
Serum potassium (mEq/l)
< 4.1 237 (32.1) 185 (30.1) 1.0
4.1–4.6 294 (39.8) 260 (42.3) 1.13 0.88–1.46
>4.6 200 (27.1) 165 (26.8) 1.05 0.79–1.39
Data are means ± SD or number of cases with percent in parentheses. Data may not yeld 100% because of missing data. * Odds ratios adjusted for 
age and gender.
Table 2: Demographic, historical, clinical and laboratory correlates of fasting plasma glucose ≥  140 mg/dl at discharge in the training 
population (Continued)BMC Geriatrics 2002, 2 http://www.biomedcentral.com/1471-2318/2/4
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A score predicting poor glycemic control was developed as
follows: each independent correlate of the outcome was
assigned a score whose magnitude was directly propor-
tional to the corresponding odds ratio. The score for ad-
mission glycemia > 218 mg/dl was arbitrarily established
to be 5, while scores of the remaining predictors were
computed according to the ratio between odds ratios of
glycemia > 218 mg/dl and that of individual predictors
obtained by the logistic regression analysis and were ap-
proximated to the unit. For example, the score of glycemia
= 143–218 was computed by solving the following pro-
portion: 2.84 : 5.29 = x : 5 and was found to be 2.7, which
was approximated to 3. Insulin therapy prior to admis-
sion and diastolic arterial pressure inferior to 80 mmHg
scored 2, Charlson's index > 2 scored 1. For each patient a
final score was obtained by summing scores of individual
predictors. Thus, a subject who used insulin prior to ad-
mission, had admission glycemia = 268 mg/dl and Charl-
son's index = 3 scored 8, i. e. 2 + 5 + 1 = 8.
Selected indexes of diabetes severity and the distribution
of the predictive score in the testing population are sum-
marized in Table 4. The distribution of the score levels was
used to compute the corresponding pairs of sensitivity
and specificity values used for drawing the ROC curve
(Figure 2) (see additional file: figure2.bmp). The area un-
der the curve was 0.72, which is consistent with a good,
but not excellent predictive model. The cut off level of the
predictive score achieving the best discrimination of pa-
tients was 4 and had sensitivity of 76% and specificity of
60%. These figures were comparable with sensitivity
(79%) and specificity (63%) achieved by the level 5 of the
In the testing population, HbA1c levels on admission and
the predictive score were highly correlated (rho = 0.58, p
< 0.001). Quartiles of HbA1c could predict the outcome
glycemic control at discharge at least as effectively as the
original and the modified predictive scores: HbA1c > 7.8
%, corresponding to the lower limit of the third quartile,
had sensitivity of 85% and specificity of 60% versus the
outcome poor glycemic control at discharge.
Table 3: Results of logistic regression analysis having plasma glucose ≥  140 mg/dl at discharge as the dependent variable in the training 
population
Fasting plasma glucose at discharge
< 140 ≥  140 OR 95% CI
Age (years) 76.8 ± 6.8 77.2 ± 6.7 1.01 0.99–1.03
Gender (males) 332 (44.9) 245 (39.8) 0.88 0.70–1.12
Diastolic blood pressure < 80 mm Hg* 101 (13.7) 126 (20.5) 1.63 1.19–2.22
Plasma glucose on admission (mg/dl)
<143 344 (46.5) 110 (17.9) 1.0 **** – ****
143–218* 233 (31.5) 218 (35.4) 2.84 2.13–3.79
>218* 162 (21.9) 287 (46.7) 5.29 3.91–7.15
White blood cells > 8970 cells/mm3 224 (30.3) 225 (36.6) 1.09 0.85–1.40
Serum sodium < 138 mEq/l 185 (25.0) 210 (34.1) 1.02 0.78–1.33
Insulin or combined hypoglycemic ther-
apy prior to admission*
100 (13.5) 151 (24.6) 2.03 1.50–2.75
Charlson's Index > 2* 281 (38.0) 273 (44.4) 1.32 1.04–1.67
Data are means ± SD or number of cases with percent in parentheses. * Marks variables found to be independently correlated with the outcome.
Figure 2
Receiving operating characteristic (ROC) curve of the pre-
dictive score versus the outcome poor glycemic control at
discharge in the testing population.BMC Geriatrics 2002, 2 http://www.biomedcentral.com/1471-2318/2/4
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When compared with the predictive score and HbA1c
>7.8% on admission, the modified predictive score
showed the best mix of sensitivity (72%) and specificity
(71%) towards the outcome HbA1c > 7% one year after
discharge (Table 5). It could target accurately diabetics at
risk of long term poor metabolic control (positive predic-
tive value: 79%), but not those likely to have their diabe-
tes well compensated one year after the discharge
(negative predictive value: 58%).
Discussion
This study demonstrates that over 50% of older diabetic
patients are discharged from wards of general medicine
and geriatrics of the acute care hospital in poor metabolic
control and can be reliably identified by an admission val-
ue of HbA1c > 7.8 % or a simple clinical prediction rule.
More importantly, these predictive tools effectively target
patients exposed to a significant risk of poor long term
glycemic control. The clinical prediction rule has greater
specificity than HbA1c > 7.8% in predicting poor long
term glycemic control, i.e. it outweighs HbA1c > 7.8% in
Table 4: Selected indexes of diabetes severity and distribution of the predictive score in the testing population *
Fasting plasma glucose at discharge
< 140 ≥  140 B SE(B) OR** 95% CI
Plasma glucose at the 
admission (mg/dl)
<143 75 (55.6) 28 (21.7) 1.0
143–218 41 (30.4) 48 (37.2) 1.16 0.31 3.19 1.73–5.89
>218 19 (14.1) 53 (41.1) 2.05 0.35 7.76 3.89–15.5
Insulin or combined 
hypoglycemic therapy prior 
to admission
56 (41.5) 79 (61.2) 0.85 0.26 2.35 1.42–3.88
Score
0 23 (17.0) 4 (3.1) 1.0
1 14 (10.4) 5 (3.9) 0.73 0.76 2.08 0.46–9.28
2 23 (17.0) 7 (5.4) 0.65 0.70 1.91 0.48–7.55
3 16 (11.9) 8 (6.2) 1.19 0.70 3.29 0.83–13.0
4 5 (3.7) 7 (5.4) 2.13 0.81 8.45 1.74–41.1
5 30 (22.2) 33 (25.6) 1.92 0.60 6.81 2.09–22.2
6 3 (2.2) 7 (5.4) 2.80 0.90 16.5 2.84–95.6
7 9 (6.7) 25 (19.4) 2.92 0.68 18.5 4.92–69.9
≥  8 12 (8.9) 33 (25.6) 2.93 0.65 18.8 5.26–67.2
* See the text, section "Results", for the method of computing the predictive score. **Adjusted for age and gender. Data in columns 2 and 3 are 
numbers (percentage).
Table 5: Sensitivity and specificity of the predictive score, HbA1c >7.8% at the admission and the modified score versus the outcome 
HbA1c >7% one year after the discharge in the testing population
Score (level 4) HbA1c >7.8% at admission Modified score (level 5)
Sensitivity, % 66 69 72
Specificity, % 71 56 71
Positive predictive value, % 81 75 79
Negative predictive value, % 57 56 58
Sensitivity: True positives/(True positives + False negatives); Specificity: True negatives/(True negatives + false positives); Positive predictive value: 
True positives/(True positives + False positives); Negative predictive value: True negatives/(True negatives + False negatives).BMC Geriatrics 2002, 2 http://www.biomedcentral.com/1471-2318/2/4
Page 9 of 11
(page number not for citation purposes)
targeting subjects who will have their diabetes well con-
trolled one year after being discharged.
Patients with more advanced diabetes, as reflected by the
systematic use of insulin at home and/or glycemia>218
mg/dl on admission, were at special risk of being dis-
charged in poor glycemic control. Hypotension on admis-
sion was another risk factor for poor glycemic control
likely because of its association with polipathology. In-
deed, physicians are expected to encounter greater diffi-
culty in tailoring the hypoglycemic therapy to the needs of
patients in more unstable conditions and to compensate
them more cautiously.
The analysis limited to the 1995–1997 period excluded
that the mechanism of the payment based upon the Diag-
nosis-Related Group could have unduly shortened the
stay and, thus, prevented the achievement of optimal gly-
cemic control. On the contrary, in the United States the in-
troduction of the Diagnosis-Related Group payment
system could have worsened the quality of care provided
to diabetic patients [31]. These observations caution
against generalizing the present results to other health sys-
tems.
Achieving a satisfactory metabolic control is the only
measure proven to prevent diabetic microvascular and
neuropathic complications [1–4]. Unfortunately, such an
objective was missed in a consistent proportion of diabet-
ic patients, as 65.8% of them had high HbA1c levels one
year after discharge. The necessity of balancing the benefit
of glycemic control towards the risk of hypoglycemia only
to some extent justifies such a result. Indeed, the protec-
tive effect of optimal glycemic control towards selected di-
abetic complications and the ensuing improvement in
quality of life largely outweigh the risk of hypoglycemic
episodes [1–4]. Furthermore, sustained improvement in
glycemic control results in significant health cost saving
with a lag time of 1 or 2 years [32]. However, our popula-
tion was older than that enrolled in the UKPDS trials and
by Wagner et al. Older age is associated with reduced sen-
sitivity to neurovegetative effects of hypoglycemia [33].
Furthermore, social factors such as lack of both formal
and informal support caution against an overzealous
treatment of diabetes, mainly in patients with cognitive
impairment or defective vision. However, lack of data on
older diabetic populations prevented us from choosing
levels of optimal metabolic control different from those
reported to protect from microvascular complications. In
this perspective, HbA1c > 7% likely represents a conven-
ient index of poor long term metabolic control, whereas
glucose ≥  140 mg/dl seems a questionable short term in-
dex of metabolic decompensation. Indeed, achieving the
optimal glycemic control might not be the primary out-
come of in-patient management if comorbidity and frailty
coexist with diabetes.
The recent experience shows that a considerable lag time
exists between the unequivocal demonstration and the in-
crease in the use of important and even lifesaving drugs
such as ace-inhibitors for congestive heart failure; never-
theless, rate of use still remains far from the optimal one
[34,35]. It is likely that the optimization of hypoglycemic
therapy will follow a similar time course. Indeed, the ben-
efit of optimal glycemic control has been definitively
proven in 1998 and further confirmed in 1999–2000.
However, a pessimistic attitude towards diabetes rather
than an insufficient knowledge of this disease seems to
hinder the implementation of management guidelines by
physicians, at least by primary care providers [36]. Fur-
thermore the poor quality of documentation sent to the
general practitioners after the patient's discharge from the
hospital could contribute to worsen the subsequent man-
agement of diabetes [37].
Selected interventions such as a cooperative strategy be-
tween general practitioners and diabetologists or the or-
ganization of mini clinics by general practitioners or
education programs can significantly improve metabolic
control [38–41]. While these interventions are generically
devoted to the average home-dwelling diabetic patients,
present findings suggest that special attention should be
paid to selected older patients discharged from the acute
care hospital. These patients should benefit from a very
careful supervision by the primary care providers and/or
from programs aimed at optimizing the home manage-
ment.
Limitations of our study deserve to be cited: 1) Fasting gly-
cemia was the only measure of short term glycemic con-
trol. A glycemic profile would have provided a more
complete and reliable estimate of the quality of therapy.
However, morning hyperglycemia has been reported to be
an uncommon consequence of nocturnal hypoglycemia
in elderly diabetics on various therapeutic regimens [42].
Thus, it is likely that only a minority of patients classified
as undertreated were exposed to an excess of hypoglyc-
emic therapy at night. 2) Conclusions apply to older hos-
pitalized patients and not to the general population. Thus,
the proposed method aims at selecting diabetic patients
amenable to special care programs after the discharge and,
thus, optimizing the use of the few available economic re-
sources. It has not been designed to target elderly homed-
welling diabetics at risk of poor metabolic control; 3) The
score was validated in a single General Medicine ward and
not on multicenter basis. Thus, we cannot assume that
discharge and therapeutic behaviors reflect those charac-
terizing most of Geriatrics and General Medicine wards.
This might limit the generalizability of results ; 4) PatientsBMC Geriatrics 2002, 2 http://www.biomedcentral.com/1471-2318/2/4
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were not systematically screened for diabetic complica-
tions. This prevented us from verifying whether the pres-
ence of complications affected the therapeutic approach
or had prognostic implications.
Conclusions
The present study shows that most of the older patients
admitted to an acute care hospital with a primary or sec-
ond-listed diagnosis of diabetes mellitus are discharged in
poor metabolic control and continue to have high HbA1c
levels one year after the discharge. Patients at risk of poor
long term metabolic control can be effectively targeted by
a simple clinical prediction rule on admission. However,
attempts should be made to improve the diagnostic accu-
racy of the proposed clinical prediction rule by including
selected presently untested variables such as the presence
and severity of diabetic complications. Finally, research is
needed to verify whether the identified predictors can be
conveniently used to select patients amenable to dedicat-
ed home care programs.
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